retatrutide triple agonist glp-1 gip glucagon phase 2 trial obesity receptor Agonism Based Therapies for retatrutide triple agonist glp-1 gip

They are grounded in endogenous biology, often supported by convergent evidence across species and experimental modalities, and frequently act at integrative nodes that coordinate multiple physiological processes

In the UK, commonly prescribed GLP-1 medications include semaglutide (Ozempic for diabetes, Wegovy for weight management), liraglutide (Victoza for diabetes, Saxenda for weight management), and dulaglutide (Trulicity for diabetes)

Additionally, GIP receptor expression in hypothalamic regions and oligodendrocytes suggests central nervous system actions that may synergize with GLP-1 to reduce appetite and food intake while potentially mitigating GLP-1-associated nausea, thereby improving treatment tolerability [36,41,42]

GIP receptor engagement increases noticeably

Individuals with insulin resistance, prediabetes, or mild metabolic dysfunction may notice improvements in energy and reduced food cravings as blood sugar becomes more stable during the day

There is no quick solve for increasing widespread access to GLP-1s for other indications